Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Narrative (Details)	12 Months Ended
	Dec. 31, 2025 USD ($) agreement	Dec. 31, 2024 USD ($)
Intangible assets
Restructuring charges	$ 1,000,000.0
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Sales
Asset impairment losses	$ 0
Customers average payment term	30 days
Distributors average payment term	60 days
Number of distribution and license agreements | agreement	3
Revenue	$ 69,258,000	$ 101,489,000
Contract assets	0	0
Impairments of long-lived assets	0	0
Goodwill impairment	0	0
Indefinite-lived intangible asset impairment	0	0
Goodwill	921,000	921,000
Research and product development	0	19,000
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent
Intangible assets
Other comprehensive loss before reclassifications unrealized gain on available for sale investments	$ 100,000
Minimum
Intangible assets
Property and equipment useful life	3 years
Market and performance-based stock unit awards service period	1 year
Maximum
Intangible assets
Property and equipment useful life	10 years
Market and performance-based stock unit awards service period	2 years
Concentrate Products Sales
Intangible assets
Reserve for returns	$ 0	0
DaVita
Intangible assets
Product purchase agreement, One time payment from counterparty		$ 400,000
DaVita | Concentrate Products Sales
Intangible assets
Revenue	2,000,000.0
Sun Pharma, Jeil Pharma, And Drogsan Pharma
Intangible assets
Recognized revenue	$ 300,000